PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

LinkedIn

Cefiderocol Matches Standard Care in Gram-Negative Bloodstream Infection

The first randomised trial dedicated to cefiderocol for hospital-acquired and health-care-associated Gram-negative bloodstream infection shows non-inferiority but no superiority, with a concerning mortality signal in metallo-beta-lactamase producers.
cefiderocolsiderophore cephalosporinGram-negative bloodstream infectioncarbapenem-resistant organismsmetallo-beta-lactamaseEnterobacteralesAcinetobacternon-inferiority trialantimicrobial resistanceIDSAstewardship IDSA
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Subscribe for Full Access →

Authors: Paterson DL, Sulaiman H, Liu PY, Chatfield MD, Yilmaz M, Salmuna ZN, Mazlan MZ, Anunnatsiri S, Sirijatuphat R, Chotiprasitsakul D, Lye DC, Somani J, Kalimuddin S, Aslan AT, Thamlikitkul V, Lee YT, Yang YS, Lin YT, Ramli WNW, Tseng CH, Archuleta S, Chan YFZ, Forde BM, Wright H, Stewart AG, Ramsay KA, Ling W, Rossi V, Harris-Brown TM, Harris PNA, GAME CHANGER Trial Investigators

Citation: Paterson DL, Sulaiman H, Liu PY, et al. Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial. The Lancet. Infectious diseases. 2026;26(2):148-159. doi:10.1016/S1473-3099(25)00469-4

Article Links: PubMed · Journal / DOI

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Suggest a correction Request a topic
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →